EP4678163A2 — Pharmaceutical composition for preventing or treating nail and skin tinea
Assigned to Individual · Expires 2026-01-14 · 0y expired
What this patent protects
Disclosed is a pharmaceutical composition for preventing or treating nail and skin tinea. The pharmaceutical composition for preventing or treating nail and skin tinea according to one embodiment may comprise: an antifungal agent; a crystal growth inhibitor; and a keratin affinit…
USPTO Abstract
Disclosed is a pharmaceutical composition for preventing or treating nail and skin tinea. The pharmaceutical composition for preventing or treating nail and skin tinea according to one embodiment may comprise: an antifungal agent; a crystal growth inhibitor; and a keratin affinity inhibitor. The composition according to one embodiment is a pharmaceutical composition which, as a topical preparation containing the antifungal agent, inhibits crystal growth during storage, prevents crystal precipitation after application, inhibits keratin affinity, and thereby has improved skin and nail permeability and antimicrobial power. The composition may comprise the antifungal agent as an active ingredient, and the crystal growth inhibitor, the keratin affinity inhibitor, a chelating agent, and additives (e.g., a vehicle, an antioxidant, or a pH adjuster) as auxiliary ingredients.
Drugs covered by this patent
- Jublia (EFINACONAZOLE) · Bausch Health
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.